Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 11, 2020

Neoadjuvant Chemotherapy and Nivolumab in Resectable Non–Small Cell Lung Cancer

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Neoadjuvant Chemotherapy and Nivolumab in Resectable Non-Small-Cell Lung Cancer (NADIM): An Open-Label, Multicentre, Single-Arm, Phase 2 Trial
Lancet Oncol 2020 Sep 24;[EPub Ahead of Print], M Provencio, E Nadal, A Insa, MR García-Campelo, J Casal-Rubio, M Dómine, M Majem, D Rodríguez-Abreu, A Martínez-Martí, J De Castro Carpeño, M Cobo, G López Vivanco, E Del Barco, R Bernabé Caro, N Viñolas, I Barneto Aranda, S Viteri, E Pereira, A Royuela, M Casarrubios, C Salas Antón, ER Parra, I Wistuba, V Calvo, R Laza-Briviesca, A Romero, B Massuti, A Cruz-Bermúdez

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading